Compare KRNY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | CAPR |
|---|---|---|
| Founded | 1884 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.5M | 584.9M |
| IPO Year | 2014 | 2011 |
| Metric | KRNY | CAPR |
|---|---|---|
| Price | $9.53 | $9.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.25 | ★ $44.63 |
| AVG Volume (30 Days) | 518.0K | ★ 4.6M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | $3.31 |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $6.23 | $2.96 |
| 52 Week High | $10.24 | $40.37 |
| Indicator | KRNY | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 51.35 |
| Support Level | $9.43 | $8.18 |
| Resistance Level | $9.74 | $11.00 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | -0.06 | 0.20 |
| Stochastic Oscillator | 5.06 | 46.93 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.